SELLAS reports survival benefit in Phase 3 leukemia vaccine trial
GPS reduced the risk of death by 41% versus best available treatment, and SELLAS plans FDA discussions and BLA preparations.
Makkler Newsroom · Nov 17, 03:25 PM · 1 min read
Market open· · CAD · Data may be delayed
Avg. target CAD 22.08 (+157.6%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.